Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. Summary
    ALKS   IE00B56GVS15

ALKERMES PLC

(ALKS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/29/2021 07/30/2021 08/02/2021 08/03/2021 08/04/2021 Date
25.56(c) 25.87(c) 26.94(c) 27.86(c) 27.97(c) Last
1 161 613 1 424 576 2 166 101 3 156 164 2 241 634 Volume
-0.81% +1.21% +4.14% +3.41% +0.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 171 M - -
Net income 2021 -79,9 M - -
Net cash position 2021 365 M - -
P/E ratio 2021 -58,7x
Yield 2021 -
Sales 2022 1 273 M - -
Net income 2022 -12,5 M - -
Net cash position 2022 466 M - -
P/E ratio 2022 4 019x
Yield 2022 -
Capitalization 4 512 M 4 512 M -
EV / Sales 2021 3,54x
EV / Sales 2022 3,18x
Nbr of Employees 2 245
Free-Float 96,7%
More Financials
Company
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and... 
Read more
More about the company
Ratings of Alkermes plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALKERMES PLC
08/04INSIDER TRENDS : Alkermes Insider 90-Day Buying Trend Prolonged with Purchase
MT
08/02ALKERMES : Secures FDA Fast Track Designation for Melanoma Treatment
MT
08/02ALKERMES : Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Trea..
PR
08/02Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Tre..
CI
07/29ALKERMES : Reports Second Quarter 2021 Financial Results
AQ
07/29ALKERMES : Mizuho Securities Adjusts Alkermes' Price Target to $33 From $29, Mai..
MT
07/29ALKERMES : SVB Leerink Adjusts Alkermes' Price Target to $25 From $23, Keeps Mar..
MT
07/28ALKERMES : Reports Earnings, Revenue Increase for Q2, Raises Full-Year Guidance
MT
07/28ALKERMES : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
07/28ALKERMES : Q2 2021 Earnings slides Final 7 27 21 607pm.pdf
PU
07/28ALKERMES : Q2 Earnings Snapshot
AQ
07/28ALKERMES : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
07/28ALKERMES PLC. : Results of Operations and Financial Condition (form 8-K)
AQ
07/28GUIDANCE : (ALKS) ALKERMES Forecasts Fiscal Year 2021 EPS Range $0.52 - $0.70
MT
07/28Alkermes plc Revises Earnings Guidance for the Full Year 2021
CI
More news
News in other languages on ALKERMES PLC
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2016Les valeurs à suivre sur les marchés américains
More news
Analyst Recommendations on ALKERMES PLC
More recommendations
Chart ALKERMES PLC
Duration : Period :
Alkermes plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 27,97 $
Average target price 25,00 $
Spread / Average Target -10,6%
EPS Revisions
Managers and Directors
Richard F. Pops Chairman & Chief Executive Officer
Iain Michael Brown Senior VP, Chief Financial & Accounting Officer
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALKERMES PLC40.20%4 512
MODERNA, INC.269.97%155 195
LONZA GROUP AG26.48%59 070
IQVIA HOLDINGS INC.39.45%47 899
CELLTRION, INC.-24.93%31 463
SEAGEN INC.-6.81%28 780